This review covers new mechanistic information spanning the past 10 years relevant to normal and abnormal thyroid growth and function that may assist in the risk assessment of chemicals inducing thyroid follicular cell neoplasia. Recent studies have shown that thyroid regulation occurs via a complex interactive network mediated through seral different mesenger syems.
Since the EPA report on thyroid follicular cell carcinogenesis was published (1), more than 600 papers on thyroid function, regulation, carcinogenesis, and epidemiology have appeared in the literature. Recent studies on regulation of the thyroid gland and thyroid follicular cell neoplasia present a broad array of new data, which add depth and complexity to the information available in 1988 on this fundamental biological process. These studies provide information on growth factors and messenger systems, the neuroendocrine control of TSH secretion, the intrinsic heterogeneity in follicular cell populations with regard to proliferative potential, and new data on thyroid cancer in both rodents and humans, including molecular genetic and cytogenetic aspects. This review of the new publications highlights selected information that is considered most relevant to the mechanisms of normal and abnormal thyroid growth and function and the action of chemicals thereon.
Thyroid Regulation
Numerous recent studies point to the conclusion that the physiological regulation of thyroid cell growth and function involves a complex interactive network of trophic factors (endocrine, paracrine, and autocrine). The effects of these factors are mediated through a number of different second messenger systems. It is well established that TSH is the main growth factor for thyroid cells, maintaining the differentiated state of the thyroid and controlling thyroid hormone secretion. Other growth regulators involved in the complex web include insulin/insulinlike growth factor-I (IGF-I), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), transforming growth factor P3 (TGF-P), and an endogenous iodide dependent mechanism (2, 3) .
TSH exerts its action on thyroid follicular cells via receptor sites, restricted mainly to the basal membranes of follicle cells (4) . The advent of recombinant DNA technology has led to the cloning of the TSH receptor of both rat (5) and human thyroid (6) (7) (8) (9) . The TSH receptor is a plasma membrane site able to bind G (guanine nucleotide-binding) protein for signal transduction (8) . G protein activation by the TSH receptor appears to be a highly complex effector system involving all four G protein families (10) . The gene for the TSH receptor is virtually constitutive in the thyroid cell, occurring far along the pathway of transformation, as demonstrated by persistent expression in normal thyroid tissue as well as in differentiated thyroid tumors, but not undifferentiated carcinoma (11) . Current models indicate that the human TSH receptor is a heptahelical glycoprotein molecule with an extremely large extracellular domain at the N-terminus, a transmembrane/intracellular region consisting of seven intramembrane helices connected by three alternating intracellular and extracellular loops, and an intracellular tail at the carboxyl terminus (12) (13) (14) . The extracellular domain is the ligand-binding site, its amino acid sequence and structure conferring a high specificity for recognition and binding of TSH, distinguishing it from other G protein-coupled receptors. It is thought that the three extracellular loops help the ligand to fit to the tertiary structure, while the intramembrane and intracellular segments appear to be critical for signal transduction. Available evidence indicates that the overall conformation of the TSH receptor in rats is probably the same as in humans, there being about 90% homology in the amino acid sequence of the rat and human receptors (6, 7, 9) .
TSH, through activation of its receptor, has been shown to stimulate more than one signal transduction pathway in the regulation of both growth and differentiated function. Each pathway may be related to specific cellular events. The main effector of TSH on proliferation and differentiation in a variety of species, humans and rats included, is the cAMP signal transduction pathway, that is, the cascade involving activation of adenylate cyclase resulting in cAMP generation (15, 16) . The binding of TSH to its receptor is believed to produce a structural change in the receptor, activating the G protein to which it is coupled.
Activation involves dissociation of the as subunit of the G protein (Gsa), in turn stimulating adenylate cyclase, thus effecting a rise in cAMP (14) .
There is increasing evidence that the physiological stimulation of thyroid cell function by TSH is achieved as well by the phosphatidyl-inositol/Ca2+ (Pi-C) signal cascade (via a G protein) with activation of phospholipase C in rat and human thyroid cells (16) (17) (18) (19) (60, 61) . In rats, a significant difference is that thyroxine-binding globulin occurs only as a postnatal surge, declining to nondetectable levels by early maturity at 8 weeks, but reappearing in senescence (62) . Thus, through most of their lives rats lack one of the major carrier proteins for T4, with transthyretin serving as the primary plasma transporter. The binding affinity of transthyretin, however, is several orders of magnitude lower than for thyroxine-binding globulin (63) . Likewise, T3 is transported in humans in a bound state to thyroxine-binding gloubulin and albumin, but only by albumin in rodents (63) . A primary function of the transport proteins is believed to be extrathyroidal storage of thyroid hormones as a mechanism to control hormone release, thereby protecting target tissues from excessive hormone influence (60) . By virtue of the absence of a major high-affinity binding protein, this buffering action protecting targets such as the thyrotrophs of the anterior pituitary would appear to be lower in rodents. Furthermore, in species in which T4 binding is limited to transthyretin and albumin, the proportion of unbound T4 is greater than it is in humans (63) . Coupled with a considerably shorter half-life for T4 of [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hr in rats compared to 5-9 days in humans (63) , these various interspecies differences imply a greater predisposition of rodents to TSH perturbation by chemicals that influence thyroid status.
There has been much recent progress in understanding the enzymatic pathways responsible for metabolism of T4, T3, and the inactive T3 analog, reverse T3 (rT3). T4 is secreted by the thyroid but has little biological activity unless deiodinated to T3. Two isoenzymes catalyze this 5'-deiodination reaction: type I 5'-deiodinase (a selenium-containing protein) abundant in liver, kidney, and thyroid, and type II '-deiodinase (lacking selenium), found primarily in brain, pituitary, and brown adipose tissue (64, 65) . In humans, about 80% of circulating T3 derives from peripheral 5'-monodeiodination of T4, particularly that by liver and kidney, while 20% of T3 is secreted by the thyroid (66) . In rats, the origin of circulating T3 is more controversial. Based on studies with selenium-supplemented and selenium-depleted rats, Chanoine et al. (65) suggested that intrathyroidal conversion of T4 to T3 provides the major source of T3 in this species. Comparatively, rat thyroidal levels of type I '-deiodinase are the highest so far reported for any species (66) .
Recent studies have also confirmed that, besides deiodination, conjugations with either glucuronic acid or sulfate are significant metabolic pathways for thyroid hormones in rats (67) (68) (69) . The enzymes responsible for glucuronidation of thyroid hormones are UDP-glucuronoysyltransferases (UDP-GT) located mainly in the endoplasmic reticulum of liver cells, but also found in intestines and kidney. It appears that there are at least three UDP-GT isoenzymes involved in rat liver. T4 and rT3 are glucuronidated by types I and II isoenzyme; T3 is glucuronidated by the type III isoform (70) . The T3 glucuronide conjugate is excreted in bile, which may represent a reversible pathway as the conjugate is hydrolyzed by intestinal bacteria, creating an enterohepatic cycle enabling reabsorption of free T3 (67, 71) . Evidence also suggests that there may be a more effective enterohepatic circulation in humans than in rats (71) .
Sulfate conjugation of thyroid hormones is an alternative metabolic pathway that enhances enzymatic deiodination and facilitates their biliary and urinary excretion. The sulfate conjugate of T3 is rapidly deiodinated by type I deiodinase through successive deiodinations of the tyrosyl (inner) and phenolic (outer) rings (72) , thus releasing iodine into the circulation for reutilization by the thyroid (73) . In humans, the majority of non-deiodinative disposal of T3 occurs via this pathway (74) .
Control of TSH Secretion in the Central Nervous System
At the central nervous system level, recent work has provided additional information on the control of TSH secretion by thyroid hormones in the anterior pituitary and via the hypothalamus. A discrete population of neurons synthesizing thyrotropin-releasing hormone (TRH), located in the paraventricular nucleus of the hypothalamus, is under negative feedback regulation by circulating thyroid hormones (75, 76) . Some results suggest that the biosynthesis of TRH is regulated by both T and T4 (77), although the mechanism by which T4 plays an inhibitory role is unknown. The negative feedback of thyroid hormones on TSH secretion caused by antithyroid compounds appears to be exerted mainly at the pituitary level. This is because the increase in TRH release into hypophyseal portal blood produced by propylthiouracil (PTU) is relatively small (less than 50%) compared to the pronounced increase (up to 20 times at 3 weeks) in serum TSH (78) . In humans, new highly sensitive immunometric assays used for measurement of TSH serum concentrations have underscored earlier work showing that thyroid hormone negative feedback on pituitary TSH secretion is mediated mainly by local generation of T3 within the pituitary from T4 by the 5 '-deiodinase enzyme system (79) . Although controversial, some data suggest that in rats serum T3 has a greater inhibitory action on TSH secretion from the pituitary than does serum T4 (80) (93, 94) , the most significant studies in this area concern the promoting activity of antithyroid compounds. These studies have used N-bis(2-hydroxypropyl)-nitrosamine (DHPN) as the initiating agent. Promoting activity in the rat has been confirmed for many antithyroid compounds, including thiourea and potassium thiocyanate (95) , PTU and potassium perchlorate (96), 4,4'-methylenebis(N,Ndimethylbenzenamine) ( (103) , and phenobarbital (100, 102) . These studies defined the effects as early but persistent decreases in circulating T3 and T4 levels and a substantial increase in circulating TSH. Particularly noteworthy are observations on sulfamethazine, for which the dose responsiveness for thyroid parameters in rats was studied with 10 dose levels spanning 3 orders of magnitude (103) . Consistently, the parameters of thyroid weight and plasma T3, T4, and TSH levels displayed nonlinear dose-response curves with a major break in linearity from zero slope at around the 1,600 ppm dose level. These data suggested that, if coincident with tumor incidence data, a benchmark approach might conceivably be applied through the most sensitive indicator to provide a scientific basis for high-to lowdose extrapolation for secondary thyroid carcinogenesis.
There is also more detailed information available on the metabolic pathways and metabolites of such antithyroid compounds as methylmercaptoimidazole (MMI) and PTU (104, 105 (110) . This striking inequality might explain the greater susceptibility of the rat to the antithyroid effects of such compounds compared to the primate.
More recent data concerning the extrathyroidal action of antithyroid compounds on the peripheral conversion of T4 and T3 involving inhibition ofT4 deiodinases primarily in liver [reviewed by Curran and De Groot (111) ] is available for PTU (102) , ATZ (112) , and phenobarbital (102, 113, 114) . Unlike PTU, ATZ did not affect the outer ring 5'-deiodination pathway but stimulated inner-ring 5-deiodination of T4, with a consequent increase in serum concentration of rT3 (112), an inactive form of T3. ATZ has no thiocarbonyl (or aromatic) group in its structure, and the lack of sulfur could be an explanation for the difference in peripheral action from PTU. The studies with phenobarbital have confirmed that this drug acts through an extrathyroidal mechanism by increasing both hepatic glucuronidation of T4 as well as increasing the clearance ofT4 from serum (102, 113, 114) .These effects were mediated by the substantial induction of the enzyme responsible for T4 metabolism, as well as an increased biliary flow. The effect of phenobarbital solely on the peripheral pathway and the less potent consequence for thyroid hormone levels, compared to the effects of a centrally acting thiourylene compound like PTU, accords with its role as a promoter rather than an inducer of rodent thyroid tumorigenesis. Recent studies also support a conclusion that 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD, dioxin) reduces thyroid hormone levels predominantly by an extrathyroidal mechanism involving potent induction of UDP-GT activity, resulting in increased hepatic T4 glucuronidation (115) . There is still no epidemiological evidence that chemicals such as phenobarbital, which affect thyroid function through a peripheral mechanism involving thyroid hormone metabolism, are associated with thyroid neoplasia in humans (111, 116 (119) and implying changes in cell type rather than in total cell number in the hypothyroid state. At the molecular level, this accords with the induction of increased levels of TSH mRNA in the anterior pituitary by PTU and a concomitant fall in growth hormone mRNA (120, 121) . The profound effect on cytoplasmic TSH levels affected both TSH a and 03 subunits in a dose-and time-dependent manner (117, 120, 122) , but the increases were relatively greater in TSH P than in the a subunit. T3 replacement reversed these specific subunit changes (117) . These various studies confirmed a direct influence of "thyroid status`on the regulation of pituitary hormones at a pretranslational level.
There is evidence that genotoxic chemicals able to induce thyroid cancer in rodents have different morphological and physiological effects from those of known goitrogens. Thus, DHPN induces rat thyroid tumors along a multistage pathway involving focal atypical hyperplasia (originating from single follicles) rather than diffuse follicular hyperplasia (123) . Furthermore, DHPN and Nnitrosomethylurea (NMU) do not appear to influence the thyroid-pituitary axis during the induction of thyroid carcinogenesis because these compounds did not increase thyroid weights unrelated to tumor development, cause a persistent elevation of serum TSH levels, or cause changes in serum T4 levels (124) (125) (126) .
Collectively, these studies with a range of compounds strengthen the hypothesis that antithyroid agents in rodents act by secondarily causing sustained elevations in serum TSH levels associated with the development of thyroid carcinogenesis. They also highlight the differences in pertinent effects between antithyroid compounds and those rodent thyroid carcinogens that are directly DNA reactive.
Epidemiology and Etiology of Human Thyroid Cancer
In humans, tumor histology is important to the understanding of the etiology of thyroid cancer because different types appear to represent separate biological entities with different clinical and epidemiological features (127, 128) . The most frequent type is papillary carcinoma, accounting for approximately 60% of all thyroid cancers; follicular carcinoma represents about 20% (129) . In Sweden, there are regional differences in the incidence of papillary and follicular types of thyroid cancer defined by iodine status, with iodinedeficient areas being associated with a higher risk of follicular cancer (128) . There is also some evidence that the incidence rates of these histological entities may be changing. The data from one study reflects an increase for papillary thyroid cancer in Sweden since 1919, but a decline for follicular cancer in cohorts born since 1939 (127) . Although residence in endemic goiter areas in Switzerland was linked to a modestly increased probability of developing thyroid cancer (130) , overall there remains a general view that no convincing evidence has yet emerged to link environmental thyroid cancer with areas of iodine deficiency. Furthermore, the long-standing program of supplementation of food items with iodine in Sweden has not affected thyroid cancer trends in iodine-deficient or iodine-rich areas (128) . Vegetables known to contain, or endogenously generate, thiocyanate have not been found to enhance the risk of thyroid cancer, but possibly exert a protective influence (131, 132) . A meta-analysis of four similarly designed case-control dietary studies conducted in high thyroid cancer areas of Switzerland and Italy revealed an association only with diets rich in starchy foods and fats, while raw ham and fish were protective (133) .
The only verified cause of thyroid cancer in humans is exposure to ionizing radiation. This association has been established for Xradiation therapy (134-137) and for radioactive fallout (138, 139) . Of the several events exemplifying the latter, the Chernobyl nuclear power plant disaster provides the most striking correlation. Since 1990, a high incidence of childhood thyroid cancer has been recorded in the Republic of Belarus, affecting predominantly children that were younger than 1 year old at the time of the accident (139) . Almost all of the cases have been papillary carcinomas with short latency (140) , in keeping with the observation that radiation-associated thyroid tumors are predominantly of the papillary type (129) . The most biologically significant isotopes released in the fallout were radioiodines, primarily 1311, and consequently radioiodine has been accepted as the causative factor (141) . This stands in marked contrast to the lack of evidence incriminating diagnostic or therapeutic doses of 1311 (142, 143) . As with the Chernobyl experience, age at the time of treatment with X-radiation therapy is also an important factor in thyroid cancer development; the 67-fold risk at 12 years mean age declines to nonsignificance at a mean age of 29 years (144) . In contrast to the risk posed by high-level ionizing radiation, a welldesigned Chinese study indicates that lifetime exposure to low-level environmental radiation, with an estimated cumulative dose of 9 cGy, is not a risk factor for human thyroid cancer (145) . Graves There is general agreement emerging that some of the genetic changes observed can be correlated with tumor histotype and stage of tumor development. Point mutations of ras are the most frequent single genetic abnormalities found in human thyroid tumors. Occurring in about 50% of follicular cell tumors (2, 153, 154) , these mutations are regarded as early molecular events in the development of this particular tumor type (155) (156) (157) (158) . Although all three ras family members have been involved (Haras, Ki-ras, N-ras), the changes have been associated mainly with Ha-ras mutation, the most common mutation site being codon 61 with glutamine to arginine substitution (156, 157, 159) . When comparing the data for thyroid cancer associated with areas of iodine sufficiency, one study found a higher rate of ras mutation in thyroid tumors from iodine-deficient areas (157) . Also prevalent in follicular adenomas are gsp mutations. Of the approximately 20 different Ga subunits of G proteins, the only one found to be mutated in thyroid neoplasia has been G5u (160) . This mutation occurs in about 25% of cases of follicular adenoma, with a possible predilection for microfollicular adenomas (3, 154, 161, 162) . Such distribution suggests that gsp mutation is another early event in the development of follicular thyroid cancer. However, there are some discrepancies between studies concerning the involvement of G proteins in thyroid neoplasia (163) , and mutations in GSa have been found in only a minority of toxic thyroid adenomas (164) .
In contrast to follicular tumors, an absence of ras and Gsa gene mutations has been recorded for papillary thyroid cancer (165) (166) . Instead, rearrangements of ret and trk, protooncogenes of the tyrosine protein kinase receptor family, are early events associated with the papillary type of cancer (158) . The redPTC rearrangement is specific for the thyroid and is found in up to 30% of human papillary carcinomas (154,167,168).
As this alteration has been detected in more than 40% of occult papillary carcinomas, generally considered to be the incipient stage of papillary malignancy, it is believed to represent an early event in the development of this tumor histotype (168) . A higher prevalence of ret protooncogene rearrangement, in up to two-thirds of cases, has now been recorded in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear reactor accident (169) (170) (171) . Unlike the situation in adult tumors and those associated with therapeutic irradiation (172) , where the most common ret translocation is retIPTC1, the alteration in the childhood radiation tumors from Belarus has been preferentially retIPTC3 (ELE/RE7) rearrangement (169-171), with several aberrant forms of fusion being described (173) . Interestingly, the only reproducible cytogenetic abnormality found in papillary thyroid cancer has been an inversion of chromosome 10 at the 10qI 1.2 locus, which is known to involve the ret protoocogene at that locus (174, 175) . As one possible mechanism linking these changes with neoplastic transformation, expression of the retIPTCI oncogene has been shown to impair the activity of certain transcription factors involved in regulating differentiated functions of thyroid cells (176) . Activating rearrangement of the trk protoocogene has also been found only in papillary carcinomas (153, 154) ; overexpression of the met oncogene is another molecular aberration observed mainly in this tumor histotype (3, 154) . Little is known concerning molecular changes involved in the transition from follicular cell adenoma to carcinoma, although a loss of heterozygosity involving chromosome 3p was considered to be specific for follicular carcinoma, appearing to correlate with the transition from the adenoma to the carcinoma stage (177, 178) . Chromosomal analysis of follicular thyroid tumors has also indicated the existence of three cytogenetically distinct subsets of adenoma, with numerical changes in chromosomes 5, 7, and 12 as the most frequent cluster of anomalies (179) . A similar cluster of alterations found in some thyroid nodular hyperplasias has been interpreted as support for a biologic continuum between hyperplastic nodules and the most common subset of adenomas (180) . At the histological level, polysomies for chromosomes 7 and/or 12 have been observed only in lesions with an exclusive or predominant microfollicular component (181) . There is some evidence from several studies that mutation of the tumor-suppressor gene p53 is a late genetic event in thyroid carcinogenesis involved in the progression to a more aggressive phenotype in the form of undifferentiated or anaplastic cancer (165, 182, 183) .
In vitro data suggest that progression to the anaplastic phenotype involves cooperative events of p53 mutation together with dedifferentiation, an epigenetic event (158) .
The role of TSH receptor gene mutations in the development of thyroid cancer is uncertain. Russo et al. (184) found activating mutations in the third intracellular loop of the TSH receptor in half of differentiated thyroid carcinomas constitutively expressing high adenylate cyclase activity. Other studies have found infrequent involvement of such genetic changes in malignant transformation of the thyroid, leading to the conclusion that mutational activation of intracellular domains of the TSH receptor is not an important mechanism of thyroid tumorigenesis (185, 186) . In contrast, somatic mutations of the TSH receptor gene are considered to be the most frequent cause of toxic thyroid adenomas, autonomous, frequently self-limiting, hyperfunctioning nodules that are not dependent on TSH (164, 187) . When introduced and expressed in thyroid cells, these mutations are able to confer TSH-independent growth, providing a specific molecular link between TSH receptor mutations and toxic adenomas (188) . The majority of toxic adenomas with constitutively activating TSH receptor mutations appear to result from clonal expansion of a single cell (18Th.
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